OBJECTIVE: To evaluate the therapeutic efficacy (in terms of overall survival [OS] and progression-free survival [PFS]) of a high-dose chemotherapy protocol including four drugs and peripheral stem cell rescue (PSCR) plus posttransplant @entity1261 (filgrastim) in disseminated @entity0 @entity1 . @entity1 AND METHODS: Fifty-three metastatic @entity0 @entity1 were treated with a four-drug program of high-dose chemotherapy including @entity786 (6 g/m2), @entity11678 (500 mg/m2), @entity3003 (800-1,600 mg/m2) and @entity2664 (20-60 mg/m2) with autologous peripheral blood progenitor cell support followed by filgrastim. Most cases (92%) had previously received conventional induction chemotherapy with @entity4349 -containing combinations. RESULTS: After a median follow-up of 27 months (range 12-43 months) from transplant, the median survival of the overall group was 25 months, with an OS projected at 43 months of 31%. @entity1 in complete remission after induction chemotherapy or status NED (no evidence of disease: surgical resection of @entity3 ) presented the best outcome, with a projected PFS of 50% at 43 months. @entity1 intensified without complete response had a poor outcome. The most important extramedullary @entity137 was @entity33 . Four @entity1 (7.5%) died as a consequence of treatment (2 with @entity295 -associated @entity649 , one with @entity409 , one with @entity712 ). CONCLUSIONS: The outcome of metastatic @entity0 @entity1 in complete remission after induction chemotherapy or NED status seems to be good with our high-dose chemotherapy including four drug and PSCR. On the other hand, @entity1 intensified without complete response presented a bad outcome and do not seem candidates for future trials with this therapeutic approach.

[High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated XXXX ].

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF'] @entity4349 :: ('CHEBI:48120', 'Chemical') :: ['anthracycline'] @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive cardiac failure'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity649 :: ('MESH:D012128', 'Disease') :: ['ARDS'] @entity11678 :: ('MESH:D013852', 'Chemical') :: ['thiotepa'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity2664 :: ('MESH:D008942', 'Chemical') :: ['mitoxantrone'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity409 :: ('MESH:D008107', 'Disease') :: ['venooclussive disease of the liver'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
